Quality of Life with Advanced Metastatic Prostate Cancer

被引：24
|
作者：
Resnick, Matthew J. [1 ,2 ]
Penson, David F. [1 ,2 ]
机构：
[1] Vanderbilt Univ, Dept Urol Surg, Ctr Surg Qual & Outcomes Res, Nashville, TN 37232 USA
[2] VA Tennessee Valley Geriatr Res Educ & Clin Ctr G, Nashville, TN 37212 USA
来源：
UROLOGIC CLINICS OF NORTH AMERICA | 2012年 / 39卷 / 04期
关键词：
Prostate cancer; Metastatic; Castrate-resistant; Quality of life; Functional status; Palliation; ANDROGEN-DEPRIVATION THERAPY; PAINFUL BONE METASTASES; SICKNESS IMPACT PROFILE; MITOXANTRONE PLUS PREDNISONE; HEALTH-STATUS; PHASE-II; RADIONUCLIDE TREATMENT; ASYMPTOMATIC MEN; RANDOMIZED-TRIAL; ZOLEDRONIC ACID;
D O I：
10.1016/j.ucl.2012.07.007
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The health-related quality-of-life (HRQOL) implications of advanced metastatic prostate cancer are variable. There are several different HRQOL instruments that measure domains germane to patients with advanced metastatic disease. The burden of prostate cancer is inversely related to the magnitude of HRQOL declines. Treatment with androgen deprivation therapy commonly results in HRQOL declines that have served as the impetus for intermittent therapy. Conversely, chemotherapeutic agents have been associated with improvements in functional status for men with castrate-resistant disease. Emerging therapies may result in significant HRQOL improvements in this population, and careful prospective evaluation of patient-reported outcomes will be required.
引用
收藏
页码：505 / +
页数：12
相关论文
共 50 条
  • [1] Impact of locally advanced or metastatic prostate cancer on the quality of life
    Lopez-Calderero, I.
    Lopez-Fando, L.
    Rios-Gonzalez, E.
    Maisonobe, P.
    Hernandez-Yuste, E.
    Sarmiento-Jordan, M.
    ACTAS UROLOGICAS ESPANOLAS, 2017, 41 (06): : 368 - 375
  • [2] Quality of life in advanced prostate cancer
    Fossa, SD
    SEMINARS IN ONCOLOGY, 1996, 23 (06) : 32 - 34
  • [3] Advanced prostate cancer and quality of life
    Portela Pereira, Paula
    Gomez-Veiga, Francisco
    ARCHIVOS ESPANOLES DE UROLOGIA, 2018, 71 (03): : 306 - 314
  • [4] Assessing quality of life and utilities in metastatic prostate cancer
    Knight, SJ
    Chmiel, JS
    Elstein, A
    Kuzel, T
    Nadler, RB
    Falcone, D
    Sharp, L
    Yang, T
    Albers, M
    Fine, R
    Moran, E
    Sharifi, R
    Bennett, CL
    JOURNAL OF UROLOGY, 1998, 159 (05): : 259 - 259
  • [5] Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials
    Adamowicz, Krzysztof
    QUALITY OF LIFE RESEARCH, 2017, 26 (04) : 813 - 822
  • [6] QUALITY OF LIFE AFTER MEDICAL VERSUS SURGICAL CASTRATION FOR LOCALLY ADVANCED OR METASTATIC PROSTATE CANCER
    Chaker, K.
    Sellami, A.
    Ouanes, Y.
    Essid, M. A.
    Dali, K. Mrad
    Abid, K.
    Mejri, R.
    Ben Rhouma, S.
    Nouira, Y.
    JOURNAL OF SEXUAL MEDICINE, 2018, 15 (07): : S285 - S286
  • [7] Assessment of quality of life in advanced, metastatic prostate cancer: an overview of randomized phase III trials
    Krzysztof Adamowicz
    Quality of Life Research, 2017, 26 : 813 - 822
  • [8] Quality of life at the end of life: Trends in patients with metastatic prostate cancer
    Melmed, GY
    Kwan, L
    Reid, K
    Litwin, MS
    UROLOGY, 2002, 59 (01) : 103 - 109
  • [9] Baseline quality of life of patients with advanced prostate cancer
    Curran, D
    Fossa, S
    Aaronson, N
    Kiebert, G
    Keuppens, E
    Hall, R
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (11) : 1809 - 1814
  • [10] Quality of life survey in patients with advanced prostate cancer
    Giannakopoulos, X
    Charalabopoulos, K
    Charalabopoulos, A
    Golias, C
    Peschos, D
    Sofikitis, N
    EXPERIMENTAL ONCOLOGY, 2005, 27 (01) : 13 - 17
12345